Jasper Therapeutics Q1 net loss $1.2M; refiles Phase 2b protocol for briquilimab in CSU

Jasper Therapeutics, Inc.

2026-Q1 EPS reported -$0.04

Cash and equivalents of $14.1M as of March 31, 2026, with $5.8M R&D and $5.1M G&A expenses.
Refiled Phase 2b protocol with FDA for briquilimab in chronic spontaneous urticaria; seeks funding to start H2 2026.
Jeet Mahal appointed CEO to lead next phase of clinical growth.
Positive clinical data: 67% of BEACON patients achieved complete response at 12 weeks; 75% in open-label achieved well-controlled disease.
Median follow-up >200 days; KIT-related AEs low-grade and resolved on study.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Jasper Therapeutics, Inc. reported the quarter ended March 31, 2026 results: net income net loss of $1.2 million, EPS basic and diluted net loss per share attributable to common stockholders of $0.04.

Period: the quarter ended March 31, 2026
Net income: net loss of $1.2 million
EPS: basic and diluted net loss per share attributable to common stockholders of $0.04
Result: reported results

Exact text from the filing

Jasper reported a net loss of $1.2 million, or basic and diluted net loss per share attributable to common stockholders of $0.04 for the three months ended March 31, 2026.

View on SEC.gov

19 earnings releases filed in the last 30 days. Browse all earnings releases →

Jasper Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-056596

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.